张晓明

发布部门：生物与医学工程学院 发布时间：2024-11-28

                                      

个人简介

张晓明，免疫学博士，入选国家级领军人才，担任科技部重点研发计划首席科学家，中国科学院分子病毒与免疫重点实验室副主任。2007年于法国巴黎第六大学获得博士学位，2007年至2012年于法国巴斯德研究所进行博士后研究。目前发表SCI论文60余篇。主持国家科技部重点研发计划1项，中国科学院前沿科学重点研究计划1项，中科院战略先导项目课题1项，国家自然科学基金重点类项目1项、集成项目课题1项、面上项目3项，上海市科委项目4项等项目。


研究方向

  1. 肿瘤免疫治疗新靶点与治疗性疫苗

  2. B细胞与创新抗体发现


荣誉及获奖情况

  1. 上海市优秀学术带头人—2023年

  2. 中国科学院前沿科学重点研究计划-“拔尖青年科学家”—2016年

  3. 中国科学院创新交叉团队负责人—2014年

  4. 上海市科技启明星计划—2012年

  5. 国家海外高层次青年人才—2011年


主持与承担主要项目情况

  1. 科技部重点研发计划：新冠病毒抗体依赖性增强作用(ADE)抗体的筛选及潜在致病机制研究，主持；

  2. 国家自然科学基金（集成项目）：解析肝癌免疫微环境的时空演进特征以指导肝癌精准诊疗的研究，课题主持；

  3. 国家自然科学基金（国际合作重点项目）：类风湿性关节炎疾病特异性淋巴细胞及分子的系统解析，主持；

  4. 国家自然科学基金（面上项目）：mTORC1通路在B1a细胞命运决定中的作用及其分子调控机制研究，主持；

  5. 中国科学院前沿科学重点项目：肝癌免疫微环境的系统解析和新型免疫靶标的发现，主持；

  6. 中国科学院战略性先导科技专项课题：肝癌免疫细胞图谱的绘制和抗体免疫应答的机制解析，主持；

  7. 上海市优秀学术带头人项目：自身反应性B细胞异常分化的分子机制研究，主持。


发表论著情况

  1. Ma JQ, Wu YC, Ma LF, Yang XP, Zhang TC, Song GH, Li T, Gao K, Shen X, Lin J, Chen YM, Liu XS, F YT, Gu XX, Chen ZC, Jiang S, Rao DN, Pan JM, Zhang S, Zhou J, Huang C, Shi S, Fan J*, Guo GJ*, Zhang XM*, and Qiang Gao*. A blueprint for tumor-infiltrating B cells across human cancers. Science. 2024, 384, eadj4857. [IF=56.9]

  2. Wu YC, Ma JQ, XP, Fang Nan F, Zhang TC, Ji SY, Rao DN, Feng H, Gao K, Gu XX, Jiang S, Song GH, Pan JM, Zhang M, Xu YN, Zhang S, Fan YH, Wang XY, Zhou J, Yang L*, Jia Fan J*, Zhang XM*, and Gao Q*. Neutrophil profiling illuminates anti-tumor antigen-presenting potency. Cell. 2024, 187:1422–1439. [IF=64.5]

  3. Dong C, Guo YC, Chen ZC, Li T, Ji J, Sun C, Li J, Cao HX, Xia YF, Xue ZH, Gu XX, Liang Q, Zhao R, Fu T, Ma JQ, Jiang S, Wu CM, Fu Q, Guo GK, Bao YF, Guo H, Yang JL, Xu M, Zhang XM*, Sheng ZZ*, and Gu ZF*. Single-cell profiling of bone marrow B cells uncovers early B cell developmental disorders associated with systemic lupus erythematosus. Arthritis Rheumatol. 2024, 76(4): 599-613. [IF=13.3]

  4. Meng L, Zha JL, Zhou BJ, Cao L, Jiang CL, Zhu YF, Li T, Lu L, Zhang JQ, Yang H, Feng J, Gu ZF, Tang H, Jiang LB, Li DF*, Lavillette D*, and Zhang XM*. A Spike-destructing human antibody effectively neutralizes Omicron- included SARS-CoV-2 variants with therapeutic efficacy. PLoS Pathog. 2023, 19(1): e1011085. [IF=7.464]

  5. Bao SH, Chen ZC, Qin DK, Xu HH, Deng XJ, Zhang RX, Ma JQ, Lu ZP, Jiang S, and Zhang XM*. Single-cell profiling reveals mechanisms of uncontrolled inflammation and glycolysis in decidual stromal cell subtypes in recurrent miscarriage. Hum Reprod. 2023, 38(1): 57-74. [IF=6.353]

  6. Ye Y, Chen ZC, Jiang S, Jia FY, Li T, Lu X, Xue, J, Lian XY, Ma JQ, Hao P, Lu LJ, Ye S, Shen N, Bao CD, Fu Q* and Zhang XM*. Single-cell Profiling Reveals Distinct Adaptive Immune Hallmarks in MDA5+ Dermatomyositis with Therapeutic Implications. Nat Commun. 2022, 13: 6458. [IF=17.694]

  7. Ye Y, Zhang XL, Li T, Ma JQ, Wang R, Wu CM, Wang RC, Bao CD, Ye S, Shen N, Guo Q*, Fu Q* and Zhang XM*. Two Distinct Immune Cell Signatures Predict the Clinical Outcomes in Patients with MDA5 positive Dermatomyositis with Interstitial Lung Disease. Arthritis Rheumatol. 2022, 74: 1822–1832. [IF=13.3]

  8. Wu YC, Yang SX, Ma JQ, Chen ZC, Song GH, Rao DN, Cheng YF, Huang SY, Liu YF, Jiang S, Liu JX, Huang XW, Wang XY, Qiu SJ, Xu JM, Xi RB, Bai F, Zhou J, Fan J, Zhang XM*, and Gao Q*. Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level. Cancer Discov. 2022, 12 (1): 134-153. [IF=38.272]

  9. Song GH, Shi Y, Meng L, Ma JQ, Huang SY, Zhang J, Wu YC, Li JX, Lin YP, Yang SX, Rao DN, Cheng YF, Lin J, Ji SY, Liu YM, Jiang S, Wang XL, Zhang S, Ke AW, Wang XY, Cao Y, Ji Y, Zhou J, Fan J*, Zhang XM*, Xi RB*, and Gao Q*. Single-Cell Transcriptomic Analysis Reveals Two Molecularly and Clinically Distinct Subtypes of Intrahepatic Cholangiocarcinoma. Nat Commun. 2022, 13: 1642 [IF=17.694]

  10. Song GH, Shi Y, Zhang MY, Goswami S, Afridi S, Meng L, Ma JQ, Chen Y, Lin YP, Zhang J, Liu YM , Jin ZJ , Yang SX, Rao DN, Zhang S, Ke AW, Wang XY, Cao Y, Zhou J, Fan J, Zhang XM*, Xi RB*, and Gao Q*. Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T cell subsets associated with disease progression. Cell Discov. 2020, 6:90. [IF=38.079]

  11. Yang HJ, Ye S, Goswami S, Li T, Wu JW, Cao CM, Ma JQ, Lu B, Pei X, Chen YN, Yu J, Xu HH, Qiu LW, Afridi S, Xiang LB and Zhang XM*. Highly immunosuppressive HLADRhi regulatory T cells are associated with unfavorable outcomes in cervical squamous cell carcinoma. Int J Cancer. 2020, 146: 1993-2006. [IF=7.316]

  12. Duan M, Goswami S, Shi JY, Wu LJ, Wang XY, Ma JQ, Zhang Z, Shi Y, Ma LJ, Zhang S, Xi RB, Cao Y, Zhou J, Fan J*, Zhang XM* and Gao Q*. Activated and exhausted MAIT cells foster disease progression and indicate poor outcome in hepatocellular carcinoma. Clin Cancer Res. 2019, 25: 3304-3316. [IF=13.801]

  13. Ma JQ, Zheng BH, Goswami S, Meng L, Zhang DD, Cao CM, Li T, Zhu FM, Ma LJ, Zhang Z, Zhang SH, Duan M, Chen Q, Gao Q* and Zhang XM*. PD1HiCD8+T Cells Correlate with Exhausted Signature and Poor Clinical Outcome in Hepatocellular Carcinoma. J ImmunoTher Cancer. 2019, 7: 331.[IF=12.469]

  14. Wu CM, Fu Q, Guo Q, Chen S, Goswami S, Sun SH, Li T, Cao XJ, Chu FY, Chen ZC, Liu M, Liu YH, Fu T, Hao P, Hao Y, Shen N, Bao CD*, and Zhang XM*. Lupus associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated. Ann Rheum Dis. 2019, 78 (8): 1090-1100. [IF=27.973]

  15. Liu M, Guo Q, Wu CM, Sterlin D, Goswami S, Zhang Y, Li T, Bao CD, Shen N, Fu Q*, and Zhang XM*. Type I interferons promote the survival and proinflammatory properties of transitional B cells in systemic lupus erythematosus patients. Cell Mol Immunol. 2019, 16: 367–379. [IF= 22.096]

  16. Zhang Z, Ma LJ, Goswami S, Ma JQ, Zheng BH, Duan M, Liu LZ, Zhang LJ, Shi JY, Dong LQ, Sun YM, Tian LY, Gao Q*, and Zhang XM*. Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma. Oncoimmunology. 2019, 8(4): e1571388. [IF=7.723]

(*：通讯作者)


联系方式

Email：xmzhang@siii.cas.cn 

办公地址：岳阳路320号/上海免疫与感染所B108室